Melane Sampson, Author at BioTuesdays

Executive Moves

Outlook’s CEO steps down; Lawrence Kenyon named interim CEO

Outlook Therapeutics (NASDAQ:OTLK) has appointed Lawrence Kenyon, EVP, CFO, and board member, as interim CEO, effective immediately. Russell Trenary has stepped down as the company’s president and CEO. Mr. Kenyon has...

December 4, 2024

Feature

Perimeter’s positive topline results signal potential for wide-spread user adoption of next-gen, ultra-high-res, AI-driven imaging tool during breast cancer surgeries

Perimeter Medical Imaging AI (TSX-V:PINK; OTC:PYNKF) is poised to transform cancer surgery, as positive topline results from a pivotal study designed to support the company’s planned FDA premarket approval (PMA)...

December 3, 2024

Developments

Medicus enters agreement with Swanielle to expand Phase 2 trial in APAC

Medicus Pharma (NASDAQ:MDCX) (TSXV:MDCX) announced a collaborative agreement with Swanielle to explore the expansion of its SKNJCT-003 Phase 2 clinical study for the treatment of basal cell carcinoma in the Asia-Pacific...

December 2, 2024

Developments

FDA accepts Revelation’s IND for Gemini in CKD

Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted its investigational new drug (IND) application for Gemini in chronic kidney disease (CKD). The company notes that the milestone enables the launch...

December 2, 2024

Developments

Elite launches generic hydrocodone and acetaminophen tables for pain management

Elite Pharmaceuticals (OTCQB:ELTP) announced it has launched a generic version of Norco tablets, a combination of hydrocodone bitartrate and acetaminophen for pain management. The generic hydrocodone bitartrate and...

December 2, 2024

Developments

CervoMed’s stock rises as FDA grants ODD to neflamapimod for dementia

CervoMed (NASDAQ:CRVO) announced that the FDA has granted orphan drug designation (ODD) to its lead investigational therapy, neflamapimod, for the treatment of frontotemporal dementia (FTD). Following the announcement...

November 28, 2024

Developments

Perimeter showcases ASBrS webinar focused on margin assessment using OCT during breast cancer surgery

Perimeter Medical Imaging AI (TSX-V: PINK; OTC: PYNKF) highlighted the November 26, 2024 webinar entitled, “Clearer Margins. Greater Confidence. Exploring the Benefits of OTC”, sponsored by the American Society of...

November 27, 2024

Developments

MaaT meets Phase 1b primary endpoint for Maat003 in ALS

MaaT Pharma (EURONEXT: MAAT) announced that its IASO Phase 1b clinical trial, evaluating the safety and tolerability of multiple doses of MaaT003 in amyotrophic lateral sclerosis (ALS), has met its primary endpoint...

November 26, 2024

Developments

IMUNON reports outcome of end-of-Phase 2 FDA meeting for IMNN-001 in ovarian cancer

IMUNON (NASDAQ: IMNN) announced the results of its end-of-Phase 2 meeting with the FDA supporting investigational interleukin-12 (IL-12) immunotherapy IMNN-001 for the treatment of advanced ovarian cancer into a 500...

November 26, 2024

Feature

Clearmind spearheading novel, life-changing psychedelic solutions for binge behaviors and mental health

Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) is discovering and developing safe, novel psychedelic-derived therapeutic candidates with its new psychoactive molecule, 5-Methoxy-2-aminoindane (MEAI), to address widespread...

November 26, 2024

Author - Melane Sampson

Outlook’s CEO steps down; Lawrence Kenyon named interim CEO

Perimeter’s positive topline results signal potential for wide-spread user adoption of next-gen, ultra-high-res, AI-driven imaging tool during breast cancer surgeries

Medicus enters agreement with Swanielle to expand Phase 2 trial in APAC

FDA accepts Revelation’s IND for Gemini in CKD

Elite launches generic hydrocodone and acetaminophen tables for pain management

CervoMed’s stock rises as FDA grants ODD to neflamapimod for dementia

Perimeter showcases ASBrS webinar focused on margin assessment using OCT during breast cancer surgery

MaaT meets Phase 1b primary endpoint for Maat003 in ALS

IMUNON reports outcome of end-of-Phase 2 FDA meeting for IMNN-001 in ovarian cancer

Clearmind spearheading novel, life-changing psychedelic solutions for binge behaviors and mental health

Subscribe